Breakthrough CAR-T Cell Therapy Targets Aggressive Brain Tumor

Researchers develop CAR-T cells that target glioblastoma, showing promise in preclinical trials with minimal toxicity.

Glioblastoma is the most common and aggressive primary brain tumor, with an average survival rate of less than two years post-diagnosis.
A team from the University of Geneva and Geneva University Hospitals identified a specific marker, PTPRZ1, on glioblastoma cells.
The newly developed CAR-T cells target this marker and exhibit a 'bystander effect,' attacking tumor cells lacking the marker while sparing healthy cells.
Preclinical trials in mice demonstrated controlled tumor growth and extended survival without significant toxicity.
Researchers are preparing for human clinical trials, aiming to offer a more effective treatment for glioblastoma.